Sunder Biomedical Tech. Co., Ltd.

As of June 30, 2026, Sunder Biomedical Tech. Co., Ltd. carries a market capitalization of 463.80M, placing it among publicly traded companies globally. Its enterprise value stands at 751.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sunder Biomedical Tech. Co., Ltd. has 60.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sunder Biomedical Tech. Co., Ltd. maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Sunder Biomedical Tech. Co., Ltd.'s stock has declined approximately 11.18% over the past 52 weeks. The 50-day moving average sits at 7.46, while the 200-day moving average is 7.97.

As of June 30, 2026, Sunder Biomedical Tech. Co., Ltd. holds 113.89M in cash and equivalents against 401.42M in total debt, resulting in a net debt position of 304.40M. Total book value stands at 773.66M, with working capital of 100.35M providing operational flexibility.